LICI Q4 FY26 Results Analysis: Normalized PAT Plunges 37%, Non-Par Surges 50%

CompoundingAI Research Updated May 21, 2026 2 min read
Neutral

LICI's Q4 FY26 numbers came in mixed, with revenue of Rs. 164,982.00 Cr (+11.60% YoY) and PAT growth of +23.20% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 21, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 164,982.00 Cr (+11.60% YoY)
PAT (Q4)Rs. 23,420.00 Cr (+23.20% YoY)
EPS (Q4)Rs. 90.78 (+19.20% YoY)
Market capRs. 506,189.64 Cr
CMPRs. 800.70

Quarter Snapshot

LIC reported 23.2% YoY PAT growth to Rs.23,420 Cr in Q4, but this was inflated by a one-time Rs.11,423 Cr tax reversal. Normalized PAT actually declined 36.9% YoY. The strategic shift to Non-Par products is working with 49.5% FY growth, and solvency improved to 2.35. However, persistency deterioration (61st month down 381 bps) and the earnings quality concern from tax reversal warrant caution. The company announced 1:1 bonus and higher dividend, signaling shareholder-friendly capital allocation.

Key Investment Insights

Key Positives

  • Gross Premium Income grew 11.6% YoY to Rs.1,64,982 Cr in Q4
  • PAT grew 23.2% YoY to Rs.23,420 Cr in Q4
  • Solvency ratio improved to 2.35 from 2.11 in FY25
  • EOM ratio improved 51 bps YoY to 11.91% in FY26
  • GNPA ratio improved 25 bps YoY to 1.21%
  • Life Non-Par premium grew 49.5% FY YoY, Linked Life grew 47.8%
  • Shareholders' net worth grew 38.9% YoY to Rs.1,75,356 Cr
  • 1:1 bonus issue announced, dividend raised to Rs.10/share

Risk Factors

  • Normalized PAT declined 4.5% YoY after adjusting for Rs.11,423 Cr tax reversal
  • 61st month persistency declined 381 bps to 59.31% - significant deterioration
  • 13th month persistency declined 20 bps to 74.64%
  • Q4 normalized PAT declined 36.9% YoY to Rs.11,998 Cr
  • Regulatory amortizations of Rs.1,523 Cr impacted Q4 EOM
  • Accounting policy change front-loaded Rs.10,959 Cr investment income
Share on X · LinkedIn

Disclaimer: This is an AI-generated analysis based on public filings. It is not investment advice, not a recommendation to buy/sell/hold any security, and is not prepared by a SEBI-registered Research Analyst or Investment Adviser.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now